Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07813559

Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease

In the field of diagnosing Thrombi diseases, it is now a well established practice to inject positron-emitting tracers into the human body.

These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own GPIIb/IIIa imaging agents.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Thrombi Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Embolism and Thrombosis Intracranial Embolism and Thrombosis Intracranial Thrombosis Nervous System Diseases Thromboembolism Thrombosis Thrombus Thrombus, Brain Vascular Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China

Loading trial locations.

About this study

This clinical research project aims to visualize abnormal tau pathology in the living human brain using [18F/68Ga]GP1 PET imaging. [18F/68Ga]GP1 is a small molcule-based tracer that offers stronger binding affinity to GPIIb/IIIa. The study primarily focuses on evaluating the safety and diagnostic efficacy of [18F/68Ga]GP1 PET imaging in human subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated thrombi (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled GPIIb/IIIa PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

  • (i) patients with non-thrombi lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Treatment and study plan

18F/68Ga-GP1

Diagnostic Test

Each subject receive a single intravenous injection of 18F/68Ga-GP1, and undergo PET/ CT or MRI imaging within the specificed time.

Primary outcomes

  1. Standardized uptake value (SUV)

    Time frame: 30 days

    Standardized uptake value (SUV) of 18F/68Ga-GP1 for each target lesion of subject or suspected thrombi.

Secondary outcomes

  1. Diagnostic efficacy

    Time frame: 30 days

    The sensitivity, specificity and accuracy of GPIIb/IIIa PET/CT were calculated.

Study contacts

Contact information is provided by the study sponsor or research team.

Haonan Yu, MD

CONTACT

[email protected]

+8613821000597

Sponsors and collaborators

Lead sponsor

Tianjin Medical University

Other

Collaborators

  • Tianjin Medical University General Hospital

Registry information

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Sep 10, 2026
Registry last updated
Sep 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.